Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $23
Oppenheimer analyst Jay Olson maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and raises the price target from $20 to $23.
JMP Securities Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $39
JMP Securities analyst Jason Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and raises the price target from $35 to $39.
Goldman Sachs Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $28
Goldman Sachs analyst Salveen Richter maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $25 to $28.
What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
Over the past 3 months, 7 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Citigroup Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $28
Citigroup analyst Neena Bitritto-Garg maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $25 to $28.
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setback For Merck’s HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours:
22 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) rose 23.7% to $3.18 in pre-market trading after jumping 10% on Monday. The company, last month, priced its IPO at $10 per unit.
Mizuho Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $26
Mizuho analyst Vamil Divan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $24 to $26.
JMP Securities Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $39
JMP Securities analyst Jason Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and raises the price target from $35 to $39.
